Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
NEPHROS INC
Bear Case (25th pct.)
-64.9% vs price
Base Case (Median)
-53.5% vs price
Bull Case (75th pct.)
-47.9% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $0.77 | -78.2% | High (40%) |
| PE Comparable | $3.64 | 3.2% | Medium (25%) |
| Graham Number | $1.84 | -47.9% | Medium (40%) |
| EV/EBITDA | $1.64 | -53.5% | Medium (20%) |
| Earnings Power Value | $1.24 | -64.8% | Medium (50%) |
Based on 5 out of 7 methods, NEPH appears overvalued at the current price of $3.53. The base case fair value of $1.64 implies 53.5% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.